Synthesis, characterization, pharmaceutical evaluation, molecular docking and DFT calculations of a novel drug (E)-5-bromo-3-(phenylimino) indolin-2-one

Abstract

Herein, one-pot synthesis of (E)-5-bromo-3-(phenylimino)indolin-2-one (5BPI molecule), density function theory for validation of the synthesized molecule, and biological activities, have been reported. Anticancer activity of the synthesized (E)-5-bromo-3-(phenylimino)indolin-2-one compound from National Cancer Institute, USA, was evaluated. However, antimicrobial nature of the molecule against 1NCO, 7C2N, 3DRA, and 4YNU proteins was also demonstrated using molecular docking as a preliminary investigation that showed the binding with ligand possess very low binding affinity as −6.22, −6.51, −5.59, and −7.45 kcal/mol, respectively. Density Functional Theory was effectively used to analyse the stability of the molecular structure under optimized circumstances, for comparative studies involving experimental and theoretical data for the gas and solvent phases. According to this analysis, UV–Vis spectra, band gap energy, nonlinear optical properties, molecular electrostatic potential, electron localization function, localized orbital locator, and reduced density gradient were illustrated in different solvents. In addition, natural bond orbital analysis was conveyed to the largest second-order perturbation energy that corresponded to electron delocalization from the donor and acceptor interaction. As a consequence, it was clearly demonstrated by the compound's drug-likeness, ADMET characteristics, docked complexes' released energies, and anticancer activity that it may be employed as a lead molecule to treat different carcinomas after the more potent alterations in their skeleton prompted by chemical reactions.